Cohen & Steers increases deemed interests in Parkway Life Reit and Digital Core Reit
⬆ $SGX(S68.SI)$ - Cohen & Steers increases deemed interests in Parkway Life Reit and Digital Core Reit Stamford Land Corporation led the buyback consideration... Continue reading on Smartkarma:- https://www.smartkarma.com/insights/cohen-steers-increases-deemed-interests-in-parkway-life-reit-and-digital-core-reit?utm_source=tiger_community By Geoff Howie, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/geoff-howie-e18941f7-03f7-4f73-a319-8fca3a24bd1f?utm_source=tiger_community On SGX (S68.SI):- https://www.smartkarma.com/entities/singapore-exchange-ltd?utm_source=tiger_community
CNS Drug Delivery Summit 2023 | 百奥赛图全人TFR1重链抗体成功将药物载荷递送入脑
百奥赛图新药BD & Licensing团队将参加于2023年12月5-7日在美国波士顿举行的中枢神经系统药物递送峰会(CNS Drug Delivery Summit),并展示一张题为“Discovery of RenNano®-derived human heavy-chain-only TFR1 antibodies that can efficiently cross the blood-brain barrier and deliver drug payloads”的海报。TFR1重链抗体(HCAbs)发现自百奥赛图专有的全人纳米抗体小鼠RenNano,在体外展示出理想的nM级亲和力和内吞活性。体内实验表明,TFR1重链抗体可有效跨越血脑屏障,并将药物载荷递送入脑;整个过程具有良好的药代动力学特征,该纳米抗体具有良好的成药潜力。纳米抗体因其体积小,应用范围广而受到药企的广泛关注。它们多具有良好的穿透性,适宜做中枢神经系统或瘤内药物递送。RenNano小鼠可产生强效的免疫反应,生成序列多样性好、亲和力适宜的纳米抗体,旨在以更短的开发时间,更低的开发成本和风险来发现全人治疗性纳米抗体。RenNano来源的重链抗体无需在体外进行人源化,可直接用于双/多抗及细胞疗法的组装。基于RenNano小鼠在全人纳米抗体开发的优势,百奥赛图今年初发起了“Nano 100计划”,旨在对包括肿瘤相关抗原(TAA)、免疫检查点、细胞因子、GPCR、神经相关因子等在内的100多个靶点进行全人纳米抗体药物开发。除了TFR1以外,如下表所示,百奥赛图还成功开发出了针对20多个靶点的全人纳米抗体。关于百奥赛图百奥赛图(股票代码:02315.HK)是一家国际性生物技术公司,专注于新型抗体类药物的研发,致力于成为全球新药发源地。基于底层基因编辑技术,百奥赛图自主研发了RenMice®(RenM